Evidence map›Paper›PMID 41695459›Full record

ArticleInflammatory intestinal diseases

De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy.

Chihiro Shiomi, Ken Kurokawa, Sozaburo Ihara, Yujiro Nishioka, Nobuhisa Akamatsu, Chie Bujo, Masaru Hatano, Junichi Ishida, Yoku Hayakawa, Yosuke Tsuji and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chihiro ShiomiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ken KurokawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sozaburo IharaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yujiro NishiokaHepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobuhisa AkamatsuHepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Chie BujoDepartment of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masaru HatanoDepartment of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Junichi IshidaDepartment of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yoku HayakawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yosuke TsujiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kiyoshi HasegawaHepato-biliary-Pancreatic Surgery Division and Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Norihiko TakedaDepartment of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Minoru OnoDepartment of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Jun KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: De novo inflammatory bowel disease (IBD) is a rare but clinically significant complication after solid organ transplantation (SOT), with incidence higher than that in the general population. Its pathogenesis, diagnostic challenges, and optimal management remain poorly defined. We describe 6 cases of de novo IBD following liver or heart transplantation and evaluate therapeutic outcomes with selective biologics targeting the IL-23 pathway. Methods: Six SOT recipients (3 liver, 3 heart) developed new-onset ulcerative colitis-type (UC-type, Results: Corticosteroids induced remission in 2 UC-type cases, while one steroid-refractory UC-type case and all CD-like cases achieved clinical improvement and endoscopic response or remission with IL-23-targeted biologics. No opportunistic infections, severe biologic-related adverse events, or graft rejection were observed. Conclusions: De novo IBD emerged years after SOT, with variable phenotypes despite baseline immunosuppression. IL-23 pathway inhibitors demonstrated favorable efficacy and safety in this vulnerable population, representing a promising strategy warranting further prospective evaluation.

Indexed as

Crohn’s diseaseDe novo inflammatory bowel diseaseIL-23 pathway inhibitorsSolid organ transplantationUlcerative colitis

Identifiers

PMID41695459
PMCPMC12904657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.